



Early and mid-term outcomes of transcatheter closure of perimembranous ventricular septal defects by using Lifetech™ Konar-MF Occluder device (MFO) – CORRIGENDUM

Corrigendum

Cite this article: Odemis E and Kizilkaya MH (2023) Early and mid-term outcomes of transcatheter closure of perimembranous ventricular septal defects by using Lifetech™ Konar-MF Occluder device (MFO) – CORRIGENDUM. *Cardiology in the Young* **33**: 2027. doi: [10.1017/S1047951122003778](https://doi.org/10.1017/S1047951122003778)

First published online: 14 December 2022

Ender Odemis and Mete Han Kizilkaya

DOI: <https://doi.org/10.1017/S1047951122003547> Published online by Cambridge University Press: 16 November 2022

The authors apologise that within the abstract and later in the article the sentence “In the follow-up, at 6th months, only four patients had hemodynamically significant residual defects” was incorrect and should have said “In the follow-up, at 6th months, only four patients had hemodynamically insignificant residual defects”.¹

The online version of this article has been updated.

Reference

1. Odemis E, Kizilkaya M. Early and mid-term outcomes of transcatheter closure of perimembranous ventricular septal defects using the Lifetech™ Konar-MF Occluder device (MFO). *Cardiol Young* 2022: 1–6. doi: [10.1017/S1047951122003547](https://doi.org/10.1017/S1047951122003547)

© The Author(s), 2022. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.